BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9198635)

  • 21. Selective killing of malignant cells from leukemic patients by alkyl-lysophospholipid.
    Verdonck LF; Witteveen EO; van Heugten HG; Rozemuller E; Rijksen G
    Cancer Res; 1990 Jul; 50(13):4020-5. PubMed ID: 2354451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia.
    Bacher U; Schnittger S; Kern W; Hiddemann W; Haferlach T; Schoch C
    Haematologica; 2005 Apr; 90(4):558-9. PubMed ID: 15820957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
    Lazarevic V; Golovleva I; Nygren I; Wahlin A
    Am J Hematol; 2006 Jun; 81(6):470-1. PubMed ID: 16680752
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effects of a lymph node extract on hemopoietic and lymphoid cells in normal state and in different forms of leukemia].
    Fediakhina RF; Rybakova LP; Tutova IIu
    Eksp Onkol; 1990; 12(4):47-50. PubMed ID: 2379487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Recent advance on chemotherapy of leukemia].
    Nakamura T; Ueda T
    Nihon Naika Gakkai Zasshi; 1994 Sep; 83(9):1531-7. PubMed ID: 7798745
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.
    Potenza L; Luppi M; Riva G; Marasca R; Martinelli S; Torelli G
    Haematologica; 2005 Sep; 90(9):1275-7. PubMed ID: 16154854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Allogenic bone marrow transplantation in acute leukemias and chronic myeloid leukemia].
    Mendeleeva LP
    Ter Arkh; 2003; 75(7):89-94. PubMed ID: 12934492
    [No Abstract]   [Full Text] [Related]  

  • 28. [Acute lymphoblastic Ph1-positive leukemia with a hybrid phenotype. The significance of the Ph1 anomaly and the hybrid phenotype].
    Nicoară S; Stefănescu D; Roman S; Tudor F; Butoianu E; Ursea C; Petrescu A; Berceanu S
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1989; 41(1):85-9. PubMed ID: 2573927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idarubicin in acute leukemia: results of US trials.
    Berman E; Raymond V; Gee TS; Kempin SJ; Gulati S; Andreeff M; Gabrilove J; Young CW; Clarkson BD; Wiernik PH
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():49. PubMed ID: 2713561
    [No Abstract]   [Full Text] [Related]  

  • 30. [Leukemia in childhood].
    Masera G; Adamoli L; Conter V; Piacentini G
    Pediatr Med Chir; 1988; 10(2):133-41. PubMed ID: 3050901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Molecular targeting therapy for leukemia].
    Miyazaki Y
    Gan To Kagaku Ryoho; 2010 May; 37(5):806-10. PubMed ID: 20524248
    [No Abstract]   [Full Text] [Related]  

  • 33. Imatinib mesylate in children and adolescents with cancer.
    Barr RD
    Pediatr Blood Cancer; 2010 Jul; 55(1):18-25. PubMed ID: 20486169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on the diagnosis of and therapy for acute promyelocytic leukemia and chronic myelogenous leukemia.
    Wujcik D
    Oncol Nurs Forum; 1996 Apr; 23(3):478-87. PubMed ID: 8801508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Classification and characteristics of acute leukemia in children].
    Adachi S
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():665-9. PubMed ID: 23134025
    [No Abstract]   [Full Text] [Related]  

  • 36. Decitabine studies in chronic and acute myelogenous leukemia.
    Kantarjian HM; O'Brien SM; Estey E; Giralt S; Beran M; Rios MB; Keating M; de Vos D; Talpaz M
    Leukemia; 1997 Mar; 11 Suppl 1():S35-6. PubMed ID: 9130691
    [No Abstract]   [Full Text] [Related]  

  • 37. Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice.
    Vasconcelos FC; Cavalcanti GB; Silva KL; de Meis E; Kwee JK; Rumjanek VM; Maia RC
    Leuk Res; 2007 Apr; 31(4):445-54. PubMed ID: 16979236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Acute myelogenous leukemia and chronic myelogenous leukemia in children].
    Adachi S
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():676-80. PubMed ID: 23134027
    [No Abstract]   [Full Text] [Related]  

  • 39. Progress and Prospects in Pediatric Leukemia.
    Madhusoodhan PP; Carroll WL; Bhatla T
    Curr Probl Pediatr Adolesc Health Care; 2016 Jul; 46(7):229-241. PubMed ID: 27283082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of leukemia with traditional Chinese drugs containing arsenic].
    Zhang T; Chen G; Zhou A
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1998 Oct; 18(10):581-4. PubMed ID: 11477838
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.